Zacks: Sientra, Inc. (NASDAQ:SIEN) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Sientra, Inc. (NASDAQ:SIEN) have received a consensus broker rating score of 2.33 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company.
Brokerages have set a 12-month consensus target price of $10.50 for the company and are expecting that the company will post ($0.58) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Sientra an industry rank of 172 out of 265 based on the ratings given to related companies.
Several research firms recently commented on SIEN. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research report on Wednesday. Stephens began coverage on Sientra in a research report on Tuesday. They issued an “overweight” rating and a $12.00 price target for the company. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Lake Street Capital initiated coverage on Sientra in a research report on Monday, April 17th. They set a “buy” rating and a $11.00 target price for the company.
Hedge funds have recently bought and sold shares of the stock. Cannell Capital LLC increased its stake in Sientra by 2.3% in the first quarter. Cannell Capital LLC now owns 1,139,571 shares of the medical instruments supplier’s stock valued at $9,595,000 after buying an additional 26,000 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in Sientra by 17.2% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 817,609 shares of the medical instruments supplier’s stock valued at $6,884,000 after buying an additional 120,226 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Sientra by 18.0% in the first quarter. Ameriprise Financial Inc. now owns 659,859 shares of the medical instruments supplier’s stock valued at $5,555,000 after buying an additional 100,445 shares in the last quarter. Schroder Investment Management Group increased its stake in Sientra by 146.1% in the first quarter. Schroder Investment Management Group now owns 417,733 shares of the medical instruments supplier’s stock valued at $3,442,000 after buying an additional 247,992 shares in the last quarter. Finally, Morgan Stanley increased its stake in Sientra by 449.6% in the first quarter. Morgan Stanley now owns 128,358 shares of the medical instruments supplier’s stock valued at $1,081,000 after buying an additional 105,005 shares in the last quarter. 76.09% of the stock is owned by hedge funds and other institutional investors.
Sientra (NASDAQ SIEN) traded up 2.34% during midday trading on Wednesday, reaching $10.94. The company’s stock had a trading volume of 458,872 shares. The firm has a 50 day moving average of $8.09 and a 200 day moving average of $8.48. The firm’s market cap is $209.11 million. Sientra has a 52-week low of $6.76 and a 52-week high of $11.17.
Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Tuesday, May 9th. The medical instruments supplier reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by $0.12. The company had revenue of $7.50 million during the quarter, compared to analysts’ expectations of $5.98 million. Sientra had a negative return on equity of 45.60% and a negative net margin of 148.22%. The company’s quarterly revenue was up 400.0% compared to the same quarter last year. Analysts anticipate that Sientra will post ($2.31) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/zacks-sientra-inc-nasdaqsien-receives-consensus-recommendation-of-buy-from-analysts-updated-updated-updated.html.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related stocks with our FREE daily email newsletter.